bullish
Pharmaron (康龙化成) A+H Listing: 3Q2019 Numbers and Thoughts on Valuation
554 Views06 Nov 2019 10:48
Pharmaron, a leading contract research company, is looking to list in Hong Kong by raising up to USD 600 million. In our previous note, we have...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Pharmaron (康龙化成) Post-IPO: A/H Convergence Post Connect Inclusion Supports A Trade02 Jan 2020
- Pharmaron (康龙化成) A+H: Allocation and Thoughts on Trading27 Nov 2019
- Pharmaron (康龙化成) A+H: Decent H/A Discount and Cornerstone Line-Up12 Nov 2019
- Pharmaron (康龙化成) A+H Listing: A Leading Drug Discovery Company28 Aug 2019
x